IC
AURA icon

Inscription Capital’s Aura Biosciences AURA Stock Holding History

Inscription Capital’s Portfolio AURA Stock Details AURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$126K Hold
17,806
– – 0.01% 755
2026
Q1 		$119K Buy
+17,806
New +$102K 0.01% 671

Other funds holding AURA

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Inscription Capital's AURA Position: Q2 2026 in Review

Inscription Capital held its Aura Biosciences (AURA) position steady in Q2 2026 at 17,806 shares worth $126K. The position accounts for 0.01% of the portfolio, ranked #755.

Inscription Capital first reported a position in AURA in Q1 2026 and has held it in 2 quarters since. 147 funds tracked by Wall St. Rank hold AURA as of Q2 2026.

  • Inscription Capital held 17,806 shares of Aura Biosciences worth $126K as of Q2 2026.
  • Inscription Capital left its Aura Biosciences share count unchanged in Q2 2026.
  • Aura Biosciences made up 0.01% of Inscription Capital's portfolio in Q2 2026, its #755 holding.
  • Inscription Capital first reported a position in Aura Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 147 funds tracked by Wall St. Rank held Aura Biosciences as of Q2 2026.

Based on Inscription Capital's 13F filing for Q2 2026, filed 13 Aug 2026.